Chari: Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set [HCQ]

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Chari et al., Blood, doi:10.1182/blood.2020008150

Chari et al., Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International.., Blood, doi:10.1182/blood.2020008150

Dec 2020 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective multiple myeloma patients showing lower mortality with HCQ treatment, unadjusted RR 0.67, p = 0.17 (data is in the supplementary material). This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.

Important missing comments or errors? Let us know.

risk of death, 33.1% lower, RR 0.67, p = 0.17, treatment 8 of 29 (27.6%), control 195 of 473 (41.2%), NNT 7.3.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Chari et al., 24 Dec 2020, retrospective, multiple countries, peer-reviewed, median age 69.0, 25 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Abstract: Regular Article LYMPHOID NEOPLASIA Clinical features associated with COVID-19 outcome in multiple myeloma: ﬁrst results from the International Myeloma Society data set Ajai Chari,1,* Mehmet Kemal Samur,2,3,* Joaquin Martinez-Lopez,4,5 Gordon Cook,6,7 Noa Biran,8 Kwee Yong,9 Vania Hungria,10 Monika Engelhardt,11-13 Francesca Gay,14 Ana Garcı́a Feria,15 Stefania Oliva,16 Rimke Oostvogels,17 Alessandro Gozzetti,18 Cara Rosenbaum,19 Shaji Kumar,20 Edward A. Stadtmauer,21 Hermann Einsele,22 Meral Beksac,23 Katja Weisel,24 Kenneth C. Anderson,2,25 Marı́a-Victoria Mateos,26 Philippe Moreau,27,28 Jesus San-Miguel,29-32,† Nikhil C. Munshi,2,25,33,† and Hervé Avet-Loiseau28,34,† 1 Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; 2Dana-Farber Cancer Institute, Boston, MA; 3Department of Data Science, Harvard T. H. Chan School of Public Health, Boston, MA; 4Instituto de Investigación, Hospital Universitario 12 de Octubre (i112), Madrid, Spain; 5Centro Nacional de Investigaciones Oncológicas (CNIO), Complutense University, Madrid, Spain; 6Leeds Institute of Clinical Trial Research and 7Leeds Cancer Centre, University of Leeds, Leeds, United Kingdom; 8John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; 9Department of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom; 10Clı́nica São Germano, São Paulo, Brazil; 11Medical Department, 12Hematology, Oncology and Stem Cell Transplantation, and 13Clinical Cancer Research Group, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 14Myeloma Unit, Division of Hematology, University of Turin/Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy; 15 Department of Hematology, Hospital de Manises, Valencia, Spain; 16Hematology Laboratory, University of Turin, Turin, Italy; 17Department of Haematology, University Medical Centre, Utrecht, The Netherlands; 18Department of Hematology, University of Siena, Siena, Italy; 19Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY; 20Division of Hematology, Mayo Clinic, Rochester, MN; 21Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; 22Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany; 23Department of Hematology, Ankara University, Ankara, Turkey; 24II Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 25Department of Medical Oncology, Harvard Medical School, Boston, MA; 26Instituto de Investigación Biomédica de Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain; 27Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France; 28Intergroupe Francophone du Myélome (IFM), Paris, France; 29Clı́nica Universidad de Navarra and 30Centro de Investigacion Medica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain; 31Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain; 32Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Pamplona, Spain; 33US Department of Veterans Affairs (VA) Boston Healthcare System, Boston, MA; and 34Centre de Recherche en Cancérologie de Toulouse, Unité 1037, INSERM, Toulouse, France The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVIDl High but..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit